End-Stage Renal Disease Market

The global end-stage renal disease market size was valued at USD 82.43 billion in 2021. It is projected to reach USD 264.90 billion by 2030, growing at a CAGR of 13.9% during the forecast period (2022–2030). End-stage renal diseases are associated with kidney-related disorders and occur during chronic kidney disease, which harms the kidney's function. The kidneys of a patient with end-stage renal disease are not functioning optimally. Urine is excreted from the body by the kidney, which aids in the removal of wastes and excess fluids. Chronic kidney disease is a term used to describe any condition that impairs kidney function. Over time, chronic kidney disease can progress to end-stage renal disease (ESRD), a condition in which the kidneys can no longer function independently. Hypertension, diabetes, smoking, and the elderly population are factors that contribute to the development of end-stage renal disease. Diabetes is the most common reason for ESRD, while hypertension (high blood pressure) is the second most common cause.

Chronic Kidney Disease (CKD) is one of the leading causes of the rising number of patients with kidney failure and is reportedly more prevalent in women than men. According to the National Kidney Foundation (NKD), approximately 10 percent of the world's population suffers from chronic kidney disease (CKD), and millions perish annually. The number of patients requiring a kidney transplant or dialysis to survive continues to grow at a rate of 5% to 7% per year.

Get more information on this report Download Sample Report

Market Dynamics

Global End-Stage Renal Disease Market Drivers

Increasing Number of Patients Suffering from Hypertension and Diabetes 

The factor contributing to the expansion of the overall market includes an increasing patient population affected by diabetes and hypertension. Diabetes is the preliminary cause of advanced kidney disease, followed by hypertension as the next most common cause. It is responsible for the development of chronic kidney disease (CKD) in approximately one-third of people living with the condition of diabetes. The primary contributor to hypertension is persistent blood pressure, which amplifies the threat of end-stage renal disease (ESRD). It is estimated that roughly 1 billion individuals suffer from this condition worldwide. As a result, the primary factor responsible for driving the market growth is the rising number of patients suffering from hypertension and diabetes.

Surge in Chronic Kidney Diseases

The ninth most standard cause of death in the US is chronic kidney disease, primarily affecting adults. Similar to this, it is anticipated that there will be an increase in renal failure cases, particularly in countries like China and India, because the elderly are more prone to renal issues. Therefore, it is anticipated that the high prevalence of ESRD will stimulate market growth during the forecast period. The rising incidence of renal failure in developed and developing nations has prompted the introduction of technologically advanced products. This innovation intends to provide patients with kidney failure satisfactory and effective results. Thus, technological advancements in treating renal failure contribute to the expansion of the market.

Global End-Stage Renal Disease Market Restraint

Lack of Awareness in the Population

The end-stage renal disease poses several difficulties, the most important of which are:

• Inconsistent renal transplant therapies' performance.
• Negative social consequences.
• General lack of awareness among the populace.

This inhibits the market for treating the end-stage renal disease from expanding.

Segmental Analysis of the Global End-Stage Renal Disease Market

The global end-stage renal disease market is segmented by treatment.

Based on treatment segment is further divided into transplant and dialysis.

The dialysis segment dominates the market and is expected to hold the largest share during the forecast period. Getting dialysis is more practical and straightforward for a patient with ESRD, and the entire procedure can be completed at residence or in a dialysis facility. Additionally, patients are not dependent on donor organs, which are much scarcer than dialysis supplies. Compared to transplant procedures, patients in developing, highly populated, or low-income countries can only get dialysis. Therefore, it is anticipated that the advantages provided by dialysis will fuel segment growth. Other factors driving the segment include rising awareness of various kidney failure diseases and unhealthy lifestyles.

Regional Analysis of the Global End-Stage Renal Disease Market

The global end-stage renal disease market analysis is segmented into four regions, namely North America, Europe, Asia-Pacific, and LAMEA.

Regional Growth Insights Request Sample Pages

The Asia-Pacific will hold the largest end-stage renal disease market share during the forecast period. This is explained by rising healthcare costs, expanding government programs, campaigns to raise awareness of chronic kidney disease (CKD), technologically advanced products, and cutting-edge healthcare facilities in the area. According to estimates, Africa and the Asia-Pacific region have the world's largest populations of people with diabetes and hypertension. Due to factors like aging population growth, lifestyle stress, a sizable population base, improving diagnosis quality, and rising patient affordability, the Asia Pacific region is anticipated to grow at the highest CAGR during the forecast period. According to estimates, the Middle East and Africa will closely follow Asia Pacific regarding CAGR.

Competitive Analysis of the Global End-Stage Renal Disease Market

• Nipro Corporation
• Fresenius Medical Care AG & Co. KGaA
• Baxter International, Inc.
• Medtronic Plc
• B. Braun Melsungen AG
• BD
• Asahi Kasei Medical Co., Ltd.
• Cantel Medical
• Nikkiso Co., Ltd.
• JMS Co. Ltd.

Recent Developments

• January 2022- Nipro established a preparatory office for setting up its U.S. Holding company in Miami, Florida, USA, and was working on setting up the company that controls our business entities in the Americas to promote further expansion of our global business and enhance regional strategy.
• May 2022- Fresenius Medical Care received FDA clearance for Versi™PD Cycler System. Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announced that the U.S. Food and Drug Administration (FDA) had awarded 510(k) clearance to the Versi™PD Cycler System1. This next-generation portable automated peritoneal dialysis system from Fresenius Medical Care North America is the lightest, smallest and quietest dialysis cycler in the United States.
• May 2022- Medtronic plc and DaVita Inc announced the intent to form a new, independent kidney care-focused medical device company to enhance the patient treatment experience and improve overall outcomes. Companies joined forces to accelerate kidney care device innovation and improve patient outcomes.

Global End-Stage Renal Disease Market: Segmentation

By Treatment 

• Transplant
• Dialysis

By Regions

• North America
• Europe
• Asia-Pacific
• LAMEA